Corvus Pharmaceuticals, Inc.
corvuspharma.com
Biotechnology
Biologics & Biosimilars
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Soquelitinib Demonstrates Efficacy in Atopic Dermatitis After Systemic Failure Dermatology Times
Albert Chiou, MD, MBA, reviews updates presented at SID 2026 on phase 1 data showing soquelitinib activity in prior systemic therapy failures, with a well-balanced adverse event profile vs placebo.
Read more
Report
ITK Inhibition With Soquelitinib Yields Sustained Skin Clearance Up to 90 Days Off Therapy Dermatology Times
Albert Chiou, MD, MBA, discusses results from the phase 1 trial of soquelitinib for moderate to severe AD presented at SID 2026.
Read more
Report
Soquelitinib Monotherapy Shrank Tumors in Pretreated T-Cell Lymphoma CURE
Final phase 1 results showed lasting responses to soquelitinib in some patients with relapsed or refractory T cell lymphoma.
Read more
Report
Report
Eczema Pill Soquelitinib: What Early Trial Results Show
An experimental once-daily pill called soquelitinib showed strong results in a Phase 1 trial for moderate to severe eczema. Here's what experts say about how it works and how it compares to Dupixent.
Read more
Report
Corvus Pharma CEO Richard Miller fields follow-up questions about last week
He discusses learnings about durability, dosing, biomarkers, and more for this first-in-class target.
Read more
Report
ASH 2025: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know
He describes the science behind ITK, and goes over ASH data in r/r T-cell lymphoma, where the company is already enrolling a pivotal study. Plus, why the profile of ITK in oncology gives him confidence in its utility for autoimmune disease, and highlighti
Read more
Report